{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:29:32Z","timestamp":1790713772201,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006974.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T00:00:00Z","timestamp":1508284800000}}],"reference-count":80,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006974.pub4","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T15:15:57Z","timestamp":1508339757000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hematopoietic stem cell transplantation for Gaucher disease"],"prefix":"10.1002","volume":"2021","author":[{"given":"Usha Rani R","family":"Somaraju","sequence":"additional","affiliation":[{"name":"Star Hospitals; Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Tadepalli","sequence":"additional","affiliation":[{"name":"SK Diagnostics; Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,18]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD006974.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e0128986","DOI":"10.1371\/journal.pone.0128986","article-title":"Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease","volume":"10","author":"Abbas","year":"2015","journal-title":"PLoS ONE [electronic Resource]"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0002|cit2","unstructured":"Almon E Novel enzyme replacement therapy for Gaucher disease; on-going phase 3 clinical trial with recombinant human glucocerebrosidase expressed in plant cells Proceedings of the 8th European Working Group on Gaucher Disease (EWGGD); 2008 June 4-7; Budapest, Hungary 2008 18"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0003|cit3","unstructured":"Baker KS Study of pulmonary complications in Pediatric Patients With Storage Disorders undergoing Allogeneic Hematopoietic stem cell transplantation www.clinicaltrials.gov"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0004|cit4","unstructured":"Barranger J Phase I study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene into peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher disease www.clinicaltrials.gov"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ymgme.2013.12.053","article-title":"EDGE: A Phase 3 study evaluating once versus twice daily dosing of eliglustat in patients with Gaucher disease type 1: Interim results from the lead-in-period","volume":"111","author":"Charrow","year":"2014","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0006|cit6","first-page":"S37","article-title":"Four-year follow-up form the ENCORE trial: a randomized, controlled, non-inferiority study comparing eliglustat to imiglucerase in patients with gaucher disease type 1 stabilized on enzyme replacement therapy","volume":"117","author":"Cox","year":"2016","journal-title":"Molecular Genetics and Metabolism"},{"issue":"9985","key":"10.1002\/14651858.CD006974.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0008|cit8","first-page":"S157","article-title":"ENCORE: a randomized, controlled, open label non-inferiority study comparing eligustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results","volume":"37 Suppl 1","author":"Cox","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0009|cit9","first-page":"S198","article-title":"The ENCORE trial: outcomes in adult patients with gaucher disease type 1 previously stabilzed on enzyme therapy after 4 years of treatment with eliglustat","volume":"39 Suppl 1","author":"Cox","year":"2016","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"9985","key":"10.1002\/14651858.CD006974.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Erratum: Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: A phase 3, randomised, open-label, non-inferiority trial (Lancet (2015) 385 (2355-2362))","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ymgme.2014.12.058","article-title":"ENCORE, a randomized, controlled, open-label non-inferiority study comparing eligustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24 month results","volume":"114","author":"Cox","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD006974.pub4-BIB0012|cit12","first-page":"S296","article-title":"Stability is maintained in adult patients with Gaucher disease type 1 (GD1) switched from velaglucerase to eliglustat: A sub-analysis of the eliglustat, phase 3 ENCORE trial","volume":"38","author":"Giraldo","year":"2015","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"21","key":"10.1002\/14651858.CD006974.pub4-BIB0013|cit13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1406.1406","article-title":"Encore - a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results","volume":"124","author":"Rosenbloom","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3324\/haematol.10635","article-title":"Low frequency maintenance therapy with imiglucerase in adult type 1 Gaucher disease: a prospective randomised controlled trial","volume":"92","author":"Fost","year":"2007","journal-title":"Haematologica"},{"issue":"7","key":"10.1002\/14651858.CD006974.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type 1 Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"QJM:Monthly Journal of the Association of Physicians"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0016|cit16","unstructured":"Elstein D Heitner R Dweck A Attias D Atarescu G Zimran A OGT918 as substrate reduction therapy in type 1 gaucher disease Proceedings of the 6th Meeting of the European Hematology Association Frankfurt, Germany 2001"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0017|cit17","first-page":"S144","article-title":"Gaucher disease: levels of inflammatory factors in patients with and without enzyme replacement therapy","volume":"37 Suppl 1","author":"Garcia","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006974.pub4-BIB0018|cit18","first-page":"S139","article-title":"Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease","volume":"33","author":"Gonzales","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1002\/14651858.CD006974.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Kishnani PS DiRocco M Kaplan P Mehta A Pastores GM A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1 Molecular Genetics and Metabolism 2009 96 4 164 70","DOI":"10.1016\/j.ymgme.2008.12.015"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0021|cit21","first-page":"405","article-title":"A phase3, randomized, double blind, placebo controlled, multi center study (ENGAGE) to investigate the efficacy and safety of eliglustat in patients with gaucher disease type 1: 9 month results","volume":"98 Suppl 1","author":"Lukina","year":"2013","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0022|cit22","first-page":"194, Abstract n","article-title":"Long-term hematologic, biomarker, and bone response to oral eliglustat in patients with gaucher disease type 1: results from a phase 2 and two phase 3 trials","volume":"101 Suppl 1","author":"Lukina","year":"2016","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0023|cit23","first-page":"S156","article-title":"Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: post-hoc comparison to imiglucerase in a real-world setting","volume":"37 Suppl 1","author":"Mankoski","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.ymgme.2014.12.207","article-title":"Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase in a real-world setting","volume":"114","author":"Peterschmitt","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.ymgme.2012.11.165","article-title":"Analysis of efficacy and safety of two iron chelators in type 1 Gaucher disease patients with iron overload","volume":"108","author":"Medrano-Engay","year":"2013","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0026|cit26","unstructured":"Mehta A A multicentre, randomised, dose frequency study of the safety and efficacy of cerezyme infusions every 4 weeks versus every 2 weeks in the maintenance therapy of patients with type 1 gaucher disease Proceedings of the 8th European Working Group on Gaucher Disease (EWGGD); 2008 June 4-7th; Budapest, Hungary 2008 11"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD006974.pub4-BIB0027|cit27","first-page":"S297","article-title":"Effects of oral eliglustat on bone parameters in treatment naive patients with Gaucher disease type 1 (GD1): 18-month results from the phase 3, randomized, placebo controlled ENGAGE trial","volume":"38","author":"Mehta","year":"2015","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.ymgme.2014.12.179","article-title":"ENGAGE - A phase 3, randomized, double-blind, placebo controlled, multi-center study to investigate the efficacy and safety of eligustat in adults","volume":"114","author":"Mistry","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ymgme.2012.11.171","article-title":"A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9 months of treatment","volume":"108","author":"Mistry","year":"2013","journal-title":"Molecular Genetics and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD006974.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0031|cit31","first-page":"S159","article-title":"ENGAGE: a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: 18-month results","volume":"37 Suppl 1","author":"Mistry","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgmr.2016.08.009","article-title":"Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial","volume":"9","author":"Pleat","year":"2016","journal-title":"Molecular Genetics and Metabolism Reports"},{"issue":"21","key":"10.1002\/14651858.CD006974.pub4-BIB0033|cit33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2275.2275","article-title":"Engage: a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1: 9 month results","volume":"122","author":"Shankar","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0034|cit34","first-page":"S160","article-title":"Plasma oligometric alpha-synuclein levels in patients with Gaucher disease is attentuated by duration of enzyme-replacement therapy","volume":"37 Suppl 1","author":"Nuzhnyi","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0035|cit35","unstructured":"Orchard P Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation www.clinicaltrials.gov"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Schiffmann R Fitzgibbon EJ Harris C DeVile C Davies EH Abel L Randomized, controlled trial of miglustat in Gaucher's disease type 3 Annals of Neurology 2008 64 5 514 22","DOI":"10.1002\/ana.21491"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.ymgme.2014.12.272","article-title":"CYP2D6 phenotype-based dosing of eliglustat","volume":"114","author":"Turpault","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0038|cit38","unstructured":"Weinreb NJ A phase 2 clinical trial of the pharmacological chaperone AT2101 for the treatment of gauchers disease Proceedings of the 8th European Working Group on Gaucher Disease (EWGGD); 2008 June 4-7; Budapest, Hungary 2008 14"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0039|cit39","article-title":"A phase 2 clinical trials of the pharmacological chaperone AT2101 for the treatment of Gaucher disease","volume":"108","author":"Weinreb N on behalf of AT2101 Study Group","year":"2008","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"5","key":"10.1002\/14651858.CD006974.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy","volume":"104","author":"Wenstrup","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Zimran A Brill-Almon E Chertkoff R Petakov M Blanco-Favela F Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease Blood 2011 118 22 5767 73","DOI":"10.1182\/blood-2011-07-366955"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.ymgme.2011.11.187","article-title":"Safety and efficacy of velaglucerase alfa in patients with type 1 gaucher disease: 2 years of treatment in phase III trials and an extension study [abstract]","volume":"105","author":"Zimran","year":"2012","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.ymgme.2012.11.280","article-title":"Long-term safety and efficacy data of taliglucerase alfa, a Plant cell-expressed recombinant glucocerebrosidase, in the treatment of naive Gaucher disease patients: 36-Month Results","volume":"108","author":"Zimran","year":"2013","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0044|cit44","first-page":"S155","article-title":"Taliglucerase alfa 36-month clinical safety and efficacy in treatment-naive patients","volume":"37 Suppl 1","author":"Zimran","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD006974.pub4-BIB0045|cit45","first-page":"S302","article-title":"Comparison of taliglucerase alfa 30 U\/Kg and 60 U\/Kg in treatment-naive pediatric patients with Gaucher disease","volume":"38","author":"Zimran","year":"2015","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.ymgme.2014.12.295","article-title":"Comparison of taliglucerase alfa 30 U\/kg and 60 U\/kg in treatment-naive pediatric patients with Gaucher disease","volume":"114","author":"Zimran","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0047|cit47","first-page":"S129","article-title":"Long-term safety and efficacy of taliglucerase alfa in pediatric patients with Gaucher disease who were treatment-naive previously treated with immiglucerase","volume":"114","author":"Zimran","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD006974.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bcmd.2014.10.002","article-title":"Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease","volume":"54","author":"Zimran","year":"2015","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"7","key":"10.1002\/14651858.CD006974.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ajh.24369","article-title":"Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naive patients with Gaucher disease","volume":"91","author":"Zimran","year":"2016","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0050|cit50","unstructured":"Zimran A Duran G Giraldo P Rosenbaum H Giona F Petakov M Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naive patients with Gaucher disease Blood Cells, Molecules & Diseases 27499018"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"236A","DOI":"10.1203\/00006450-198404001-00856","article-title":"Bone marrow transplantation (BMT) in Gaucher's disease","volume":"18","author":"August","year":"1984","journal-title":"Paediatric Research"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0052|cit52","first-page":"3635","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","volume":"III","author":"Beutler","year":"2001"},{"issue":"3","key":"10.1002\/14651858.CD006974.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/0971-6866.19530","article-title":"The treatment of Gaucher disease in countries with limited health care resources","volume":"11","author":"Beutler","year":"2005","journal-title":"Indian Journal of Human Genetics"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/08035320600619039","article-title":"Gaucher disease: multiple lessons from a single gene disorder","volume":"Suppl 451","author":"Beutler","year":"2006","journal-title":"Acta Paediatrica"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0055|cit55","first-page":"327","article-title":"Bone marrow transplantation in Gaucher's disease: effect of mixed chimeric state","volume":"14","author":"Chan","year":"1994","journal-title":"Bone Marrow Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006974.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00005792-199511000-00002","article-title":"Gaucher Disease","volume":"74","author":"Danuta","year":"1995","journal-title":"Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006974.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-2008-1071549","article-title":"Enzyme replacement therapy of infantile Gaucher disease","volume":"24","author":"Erikson","year":"1993","journal-title":"Neuropediatrics"},{"issue":"7414","key":"10.1002\/14651858.CD006974.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0059|cit59","unstructured":"Higgins JPT Altman DG Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"8542","key":"10.1002\/14651858.CD006974.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(87)91673-4","article-title":"Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher's syndrome","volume":"1","author":"Hobbs","year":"1987","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2141.2004.05351.x","article-title":"Gaucher disease: pathological mechanisms and modern management","volume":"129","author":"Jmoudiak","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD006974.pub4-BIB0062|cit62","first-page":"128","article-title":"Haematopoietic stem cell transplantation: current status","volume":"20","author":"Kumar","year":"2007","journal-title":"National Medical Journal of India"},{"key":"10.1002\/14651858.CD006974.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ejim.2006.07.005","article-title":"Epidemiology and natural history of Gaucher's disease","volume":"17","author":"Mehta","year":"2006","journal-title":"European Journal of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006974.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/106002809603000411","article-title":"Gaucher's Disease: A Review","volume":"30","author":"Morales","year":"1996","journal-title":"Annals of Pharmacotherapy"},{"issue":"24","key":"10.1002\/14651858.CD006974.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival end-points","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006974.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1703839","article-title":"Haematopoietic stem cell transplantation for Inherited metabolic diseases: an overview of outcomes and practice guidelines","volume":"31","author":"Peters","year":"2003","journal-title":"Bone Marrow Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1056\/NEJM198407123110203","article-title":"Bone-marrow transplantation In severe Gaucher's disease","volume":"311","author":"Rappeport","year":"1984","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006974.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00007890-198807000-00011","article-title":"Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease","volume":"46","author":"Ringden","year":"1988","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006974.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00007890-199503000-00011","article-title":"Ten years experience of bone marrow transplantation for gaucher disease","volume":"59","author":"Ringden","year":"1995","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006974.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.11193","article-title":"Therapy of adult Gaucher disease","volume":"92","author":"Schmitz","year":"2007","journal-title":"Haematologica"},{"issue":"720","key":"10.1002\/14651858.CD006974.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1259\/0007-1285-60-720-1189","article-title":"Regression of the radiological changes of Gaucher's disease following bone marrow transplantation","volume":"60","author":"Starer","year":"1987","journal-title":"British Journal of Radiology"},{"issue":"12","key":"10.1002\/14651858.CD006974.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/adc.2005.074278","article-title":"Haemopoietic stem cell transplantation for genetic disorders","volume":"90","author":"Steward","year":"2005","journal-title":"Archives of Disease in Childhood"},{"issue":"4-5","key":"10.1002\/14651858.CD006974.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000112184","article-title":"Norbottnian type of Gaucher disease - Clinical, Biochemical and Molecular Biology aspects: Successful treatment with Bone marrow transplantation","volume":"13","author":"Svennerholm","year":"1991","journal-title":"Developmental Neuroscience"},{"issue":"5","key":"10.1002\/14651858.CD006974.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1203\/00006450-199205000-00019","article-title":"Allogeneic Bone marrow transplantation in Severe Gaucher disease","volume":"31","author":"Tsai","year":"1992","journal-title":"Pediatric Research"},{"issue":"4","key":"10.1002\/14651858.CD006974.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1023\/A:1005367328003","article-title":"Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase","volume":"20","author":"Young","year":"1997","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"8947","key":"10.1002\/14651858.CD006974.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(95)90432-8","article-title":"Enzyme replacement therapy in type 1 and type 3 Gaucher's disease","volume":"345","author":"Zimran","year":"1995","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD006974.pub4-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006974","article-title":"Hematopoietic stem cell transplantation for Gaucher disease","author":"Somaraju","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006974.pub4-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006974.pub2","article-title":"Hematopoietic stem cell transplantation for Gaucher disease","author":"Somaraju","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD006974.pub4-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006974.pub2","article-title":"Hematopoietic stem cell transplantation for Gaucher disease","author":"Somaraju","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD006974.pub4-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006974.pub3","article-title":"Hematopoietic stem cell transplantation for Gaucher disease","author":"Somaraju","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006974.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T08:47:15Z","timestamp":1635756435000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006974.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,18]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006974.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,18]]}}}